Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-09-0473
European Journal of Endocrinology, Vol 161, Issue 4, 529-532
Copyright © 2009 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
EJE-09-0473v1
161/4/529    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Terzolo, M.
Right arrow Articles by Angeli, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terzolo, M.
Right arrow Articles by Angeli, A.

COMMENTARY

Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research

Massimo Terzolo, Giuseppe Reimondo and Alberto Angeli

Medicina Interna I, Dipartimento di Scienze Cliniche e Biologiche, Facoltà di Medicina e Chirurgia San Luigi Gonzaga, Università di Torino, ASO San Luigi Gonzaga, Regione Gonzole, 10, 10043 Orbassano, Torino, Italy

(Correspondence should be addressed to M Terzolo; Email: terzolo{at}usa.net)

Clinical endocrinologists have to deal frequently with adrenal incidentalomas in their practice. However, no comprehensive guidelines have been published by professional societies to guide assessment and management of adrenal incidentalomas and current recommendations are mainly based on the NIH state-of-the-science statement or expert opinions. An accompanying paper in this issue of the journal provides a critical revision of the relevant literature on this clinically important topic. The provocative conclusion of the authors is that current recommendations are burdened by high costs, little clinical benefit and also risk of inducing cancer. This paper has the merit to outline the limits of proposed protocols and to stimulate fruitful discussion; however, many aspects represent the personal view of the authors rather than evidence-based assumptions. The purpose of the present comment is to provide a more balanced view addressing the arguments that are condivisible and those that are based on inconsistent data. To add further to the argument of discussion, we also outline a clinically-oriented strategy for follow-up. In conclusion, the need for further research appears evident to define more efficient guidelines.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 European Society of Endocrinology.